
Why No Two Chemotherapy Plans Are Alike: The Science of Personalised Treatment
By Dr Amit Ghanekar
A chemotherapy plan is not selected simply because a person has cancer. Oncologists choose a regimen by matching the biology and extent of the cancer with the purpose of treatment, evidence for particular drugs, and the patient's ability to tolerate them. Even two people with the same cancer diagnosis may therefore receive different drugs, doses, schedules, or numbers of cycles.
The Diagnosis Is Only the Starting Point
Cancer names such as breast cancer, lung cancer, lymphoma, or colorectal cancer describe broad disease categories. Within each category are biologically distinct diseases that can behave differently and respond differently to treatment.
Histology, which examines the type and microscopic characteristics of cancer cells, is one part of this classification. Depending on the cancer, clinicians may also consider tumour grade, stage, receptor expression, molecular alterations, cytogenetic abnormalities, or other biomarkers.
This matters because chemotherapy works by exploiting particular vulnerabilities in malignant cells, especially processes involved in cell division and DNA replication. Different cytotoxic drugs interfere with these processes in different ways.
For example, some agents damage DNA or interfere with its replication. Others disrupt enzymes required for DNA function or interfere with the microtubules that cells need to divide. These mechanisms are not interchangeable. A regimen that is established for one malignancy may have little or no therapeutic role in another.
Personalised chemotherapy treatment therefore begins with a more specific question than "Which chemotherapy treats cancer?" The relevant question is: which systemic treatment has evidence of benefit for this particular cancer in this particular clinical setting?
Treatment Intent Changes the Entire Plan
The same chemotherapy drug can be used for very different reasons.
Adjuvant chemotherapy
Adjuvant chemotherapy is given after definitive local treatment, usually surgery, when there may be no visible cancer remaining. Its purpose is to eradicate microscopic malignant cells that could remain elsewhere in the body and thereby reduce the risk of recurrence.
Neoadjuvant chemotherapy
Neoadjuvant chemotherapy is administered before the main local treatment. In selected cancers, it may reduce tumour size, make surgery more feasible, provide information about treatment response, or form part of an established multimodality treatment strategy.
Treatment for advanced disease
When cancer has spread and cure is not realistically achievable with systemic treatment, chemotherapy may be used to control disease, relieve cancer-related symptoms, delay progression, or prolong survival where evidence supports a benefit.
These distinctions influence how benefit and toxicity are weighed. A temporary treatment delay or dose modification, for example, has to be interpreted within the purpose of therapy and the evidence supporting that particular regimen. It does not automatically mean that treatment has failed.
Why Chemotherapy Often Uses More Than One Drug
Many chemotherapy protocols combine two or more agents rather than relying on a single drug.
Combination chemotherapy can attack malignant cells through different mechanisms. It may also reduce the chance that a population of cancer cells resistant to one mechanism will determine the entire treatment response.
But adding drugs also changes toxicity.
One component of a regimen may predominantly suppress bone marrow function, while another may be associated with peripheral neuropathy, renal injury, mucosal damage, or other organ-specific adverse effects. Clinicians therefore consider the efficacy of the combination alongside whether its expected toxicities are acceptable for the individual patient.
This is why the name of a chemotherapy drug alone tells only part of the story. The dose, combination, treatment interval, number of planned cycles, route of administration, and accompanying supportive therapy collectively form the regimen.
Body Size Helps Calculate Dose, but It Does Not Settle the Dose
Many cytotoxic chemotherapy doses are initially calculated using body surface area, commonly expressed in milligrams per square metre. Some drugs use other dosing methods.
The calculated value is a starting framework rather than proof that every patient should receive exactly the same treatment intensity.
Oncologists may need to account for organ function, previous treatment, existing toxicities and regimen-specific dosing rules. Maintaining adequate dose intensity, meaning the amount of chemotherapy delivered over a defined period, can be important in some curative treatment settings. At the same time, administering treatment without considering clinically significant toxicity can expose a patient to avoidable harm.
Dose reduction is therefore not synonymous with treatment failure. Nor should a patient independently alter a chemotherapy dose. Dose modification is a clinical decision made in the context of the regimen, treatment objective and the patient's condition.
Kidney and Liver Function Can Alter Drug Exposure
Two patients given the same nominal dose do not necessarily process a drug identically.
Chemotherapy agents differ in how they are metabolised and eliminated. Renal function is particularly relevant for drugs or metabolites that depend substantially on the kidneys for clearance. Impaired clearance can increase systemic drug exposure and, for some agents, the risk of toxicity.
Hepatic function can matter for drugs metabolised or eliminated through the liver and biliary system.
This is one reason blood tests may be performed before chemotherapy cycles. Renal and hepatic results are interpreted alongside the specific treatment being used, the patient's clinical condition and protocol requirements. An abnormal laboratory value does not, by itself, determine whether treatment must proceed, be modified, or be delayed.
Bone Marrow Reserve Can Become a Limiting Factor
Many cytotoxic agents affect rapidly proliferating cells. Cancer cells may divide rapidly, but they are not the only cells in the body that do so.
Bone marrow contains precursor cells that continually generate neutrophils, red blood cells and platelets. Chemotherapy-induced suppression of these precursors can therefore cause myelosuppression.
The consequences can include:
neutropenia, a reduction in infection-fighting neutrophils
anaemia, reflecting reduced red blood cell production
thrombocytopenia, which means a reduced platelet count
The absolute neutrophil count and platelet count can be particularly relevant when assessing recovery before a subsequent treatment cycle.
Neutropenia should also be distinguished from febrile neutropenia. The latter involves fever occurring in the setting of significant neutropenia and can represent a medical emergency because the normal inflammatory response to infection may be impaired.
Previous chemotherapy, radiotherapy involving substantial bone marrow, underlying marrow disease and prior episodes of significant myelosuppression can all influence subsequent treatment decisions.
Age Alone Does Not Describe Treatment Fitness
Chronological age provides incomplete information about physiological reserve.
An older adult who remains independent with preserved organ function may tolerate treatment differently from another person of the same age with frailty, impaired mobility, multiple comorbidities or reduced nutritional reserve. Conversely, being younger does not guarantee that intensive chemotherapy is appropriate.
Oncology teams may therefore assess performance status, which describes how well a person can perform ordinary activities, alongside cardiovascular health, kidney and liver function, nutritional status, other illnesses and previous treatment.
Comorbidities can be especially important when a regimen has a recognised organ-specific toxicity. Pre-existing neuropathy, for example, may influence decisions around a drug known to cause peripheral neuropathy. Certain regimens associated with cardiac toxicity may require assessment of cardiovascular function in appropriate patients.
The First Chemotherapy Plan Is Not Necessarily the Final One
Chemotherapy planning continues after treatment begins.
Before or during subsequent cycles, clinicians may evaluate the patient's symptoms, physical condition, complete blood count, renal or hepatic function and treatment-specific toxicities. Other investigations depend on the regimen and clinical circumstances.
Response is assessed separately.
Imaging may be performed at defined points in treatment for many solid tumours. Physical examination, disease-related symptoms and selected tumour markers can contribute information in appropriate cancers. Haematological malignancies may require different disease-specific response assessments.
A tumour becoming smaller represents a response, but response is not automatically equivalent to cure. Similarly, stable disease in advanced cancer can represent clinically meaningful disease control when preventing progression is an objective of treatment.
If substantial toxicity develops, the oncology team may alter the dose, delay a cycle, change supportive treatment or, in some circumstances, reconsider the regimen. These decisions depend on both the severity of toxicity and what the treatment is intended to achieve.
Personalisation Does Not Mean Every Regimen Is Invented From Scratch
There is an important limit to the term "personalised."
Oncologists do not ordinarily design an entirely new chemotherapy combination for every patient. Treatment is generally based on established evidence, recognised protocols and disease-specific guidelines. Personalisation occurs within that evidence-based framework.
The clinician selects an appropriate treatment strategy and then considers whether patient-specific factors require modification, additional monitoring or an alternative established approach.
Modern cancer treatment has also expanded beyond cytotoxic chemotherapy. Depending on tumour biology, treatment may involve targeted therapy, immunotherapy, endocrine therapy or combinations of systemic treatments. These therapies should not all be described as chemotherapy because their mechanisms, indications and toxicity profiles differ substantially.
What Patients Should Understand About Their Own Plan
A useful chemotherapy discussion goes beyond asking for the names of the drugs. Patients and caregivers can ask the oncology team what the treatment is intended to achieve, why the particular regimen was selected, how many cycles are planned, how response will be assessed and which toxicities are especially relevant to those drugs.
It is also reasonable to understand what blood tests or other assessments are required before treatment and which symptoms should prompt contact with the treating team.
The differences between chemotherapy plans are not random variations in practice. They reflect the central principle of medical oncology: effective systemic treatment requires the characteristics of the cancer, the evidence for the regimen, treatment intent and the patient's physiology to be considered together. The prescription may appear as a list of drugs and doses, but behind it is an ongoing clinical calculation of expected benefit, biological behaviour, treatment exposure and tolerability.
